Results from the first cohort of the AURORAX 087A study show the new biomarker-based test provides a more robust basis for making decisions on treatment than scans alone
Researchers have developed a simple urine test to measure the severity of cystic fibrosis and assess new treatments
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.